Objectives: Interferon-β (IFN-β) is used in the treatment of multiple sclerosis (MS). 
| INTRODUCTION
The type I interferon, interferon-β (IFN-β) has been used in the induction was required for the suppression by IFN-β of IFN-γ induction by IL-12. 4 Production of type I IFN is deficient in patients with MS, and several studies showed a decreased responsiveness of patients with MS to IFN type I, 5, 6 reflected, for example, in reduced expression of IFNstimulated genes and decreased phosphorylation of STAT1.
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The aim of this study was to determine the effects of IFN-β on the phosphorylation of STAT4 in patients with MS compared with controls as an indication of response to IFN-β, and to determine its relationship with the expression of interferon type 1 receptor (IFNAR). We also aimed to determine whether the effects of IFN-β on phosphorylation of STAT4 in patients with MS correlate with their 5-year clinical course as measured by the change in the expanded disability scale (EDSS) score and clinical relapses.
| MATERIALS AND METHODS
The Nottingham Research Ethics Committee (UK) approved this study.
| Subjects included in the study
Twenty-seven relapsing-remitting patients with MS (17 women, 10 men; age range 29-60, mean age 43; mean expanded disability status scale, EDSS 3.6, range 1-6) and 12 healthy controls (seven women and five men; mean age 42) were included in the study. The patients with MS had not previously received disease-modifying drugs, were clinically stable at baseline (not in relapse) and had had two relapses in the last 2 years. Participants gave written informed consent prior to participation in the study.
In all MS subjects, treatment with IFN-β was commenced as part of their clinical care. Twenty-four patients were treated (13 with IFN-β 1b and 11 with IFN-β 1a), and all patients were followed up in clinic for 5 years. EDSS at 5 years of follow-up was compared with initial EDSS score.
| Cytokines and antibodies
The following reagents were obtained: IFN-β (Rebif, a gift from Merck Serono, UK); polyclonal rabbit anti-STAT4 antibody, polyclonal rabbit anti-phospho-STAT4 antibody (Zymed Laboratories, Inc., San
Francisco, CA, USA); antihuman IFN-α receptor-1 (IFNAR-1) mAb and mouse IgG isotype control were purchased from R&D Systems (Oxford, UK).
| Cell preparation
Peripheral blood mononuclear cells (PBMCs) from healthy donors and patients with MS were isolated by standard gradient centrifugation with Histopaque 1077 (Sigma-Aldrich, Dorset, UK). The mononuclear cells were prepared at 1×10 6 cells/ml in media consisting of RPMI 1640, 2 mM glutamine, 20 mM Hepes, 0.1 mg/ml penicillin and streptomycin, and 10% FCS (Sigma-Aldrich). 
| Cell stimulation

| Surface staining
Following incubation with IFN-β, 1×10 6 cells/ml were washed by centrifugation in 2% FCS RPMI, and 10 μl IFNAR-1 antibody was added for 30 minutes. After washing, cells were incubated with 5 μl goat anti-mouse FITC or goat anti-rat-PE, for 30 minutes, then washed and resuspended in 0.5% formaldehyde.
| Quantitative real-time polymerase chain reaction (PCR)
RNA was extracted using RNeasy miniprep kit (Qiagen, Valencia, CA, USA) following manufacturers' instructions. First-strand cDNA synthesis was initiated from 0.5 μg total RNA, using random hexamers CA, USA) as specified by the manufacturer. PCRs were performed in triplicate on a MX4000 ® Multiplex System (Stratagene) using standard default thermal cycling conditions. Non-template controls were loaded in triplicate. Quantification of transcripts was carried out using the relative standard curve method as per Applied Biosystems (Foster City, CA, USA; 1997). 9, 39 An equal aliquot of undiluted cDNA from each sample was pooled together. 39 This pool was serially diluted (neat, 1:2, 1:5, 1:10, 1:20) to produce standards, from which the Ct value was converted to ng total RNA equivalent used for first-strand synthesis.
mRNA expression for each gene is normalized to internal standard (β2 microglobulin expression).
| Measurements
Peripheral blood mononuclear cells were evaluated on Epics XL flow cytometer (Beckman Coulter, Fullerton, CA, USA), and the results were analysed using software WINMDI 2. 
| RESULTS
| Activation of STAT4 by IFN-β
We first confirmed previous results showing that IFN-β increases We then compared STAT4 activation in patients and controls. 
| IFNAR expression in patients and controls
We next investigated upstream of STAT4, at the receptor level.
IFNAR-positive cells, by flow cytometry with IFNAR1 antibody, were 15%±2% for MS v. 36%±7% for controls. IFNAR expression was lower (P=.034) in patients with MS compared with controls ( Figure 2 ).
We then assessed IFNAR1 and IFNAR2 mRNA expression in 
| DISCUSSION
Here, we show that untreated patients with MS have reduced IFN responses as reflected by reduced STAT4 activation due to reduced IFNAR expression.
In our treatment-naive patients with MS, IFNAR1 expression was significantly lower than in controls. This confirms previous reports on IFNAR subtypes mRNA pointing to lower IFNAR1 mRNA levels in untreated patients with MS than in healthy controls. 10, 11 The mechanism may involve downregulation of IFNAR by inflammatory cytokines, as we showed. 4 High levels of gene expression of IFNAR correlate with greater biological response to IFN-β as measured by terferon-β bioactivity. 12 Other authors have shown that long-term treatment with IFN-β could increase the levels of IFNAR1 mRNA in subjects in whom MxA has been induced. 10 Low levels of expression of the IFNAR subunits can be one of the causes of low responsiveness to IFN-β in MS.
STAT4 signalling has been associated with Th1 development, inflammation and autoimmunity; however, its roles are not completely understood. STAT4 Th1 signalling suppresses Foxp3-positive T regulatory cells (Treg) and favours autoimmune disease. 13 The transition of a subset of Th17 precursors to Th1-like cells is contingent upon STAT4 expression.
14 STAT4 represents a core signalling hub in MS. 4 4 In progressive stages of MS, IL-10 loses its ability to suppress IFN-γ and IL-12, while IFN-β treatment loses efficacy considerably in this phase of the disease. Therefore, the beneficial immunomodulatory effects of IFN-β may in part be a result of its ability to suppress IL-12. 4 The type I IFN pathway of STAT4 activation is more important in human immune responses than in mouse. 21 Type I IFN-induced STAT4 activation requires interactions of STAT4 with STAT2, and there is genetic dissimilarity between murine and human STAT2. 
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Immune priming can change, positively or negatively, the quantity and quality of signal transduction by type I IFNs. 24 The decreased STAT4
signalling in response to IFN-β found in the PBMC in the group of untreated patients with MS reported here could therefore reflect the baseline MS immunological milieu in the absence of therapeutic immunomodulation.
Because of the role of STAT4 in mediating inflammation in MS and, at the same time, in mediating IFN-β anti-inflammatory effects, we planned to look at long-term clinical correlates of STAT4 activation in untreated patients with MS just prior to initiating disease-modifying treatment with IFN-β. The patient group was then followed up for 5 years. Disability progression at 5 years is often used as a measure of long-term response to treatments in MS. 27, 28 Of note, the patients in this study were early participants in the UK Multiple Sclerosis Risk Sharing Scheme. 29 This large observational clinical cohort study recently showed that treatment with IFN-β reduces disability progression measured by EDSS scores over 6 years of treatment. 29 Early inclusions in the Risk Sharing Scheme (and access to treatment with IFN) consisted predominantly of patients with longer disease duration and F I G U R E 3 IFNAR mRNA expression. IFNAR1 and IFNAR2 mRNA expression measured using real-time PCR (relative to internal control: β2 microglobulin). Peripheral blood mononuclear cell obtained from untreated patients with MS (n=27) and controls (n=12) had similar IFNAR 2 expression; however, IFNAR1 expression was significantly lower in patients with MS when compared to controls (P=.028). Bars represent the normalized median value in arbitrary units, and error bars represent interquartile range. ★P=.028; NS, not significant Nevertheless, a reliable documentation of relapses was possible only in the 22 of patients followed (81%), and under-reporting of MS relapses cannot be excluded. In a multicentre, retrospective study including 103 patients with MS from 7 UK centres, 46% of patients did not report at least one relapse in the past and 28% of most recent relapses were unreported. 32 Several reasons may contribute to this, including rare review schedules. 32 The occurrence of relapses remains the principal factor for starting disease-modifying treatments (DMTs) under current MS treatment guidance. 33 The risk of severe MS relapses is lower in patients treated with DMTs. 34 While cost-effectiveness analyses in MS tend to focus on long-term disability, individual relapses have a major impact on patients‫׳‬ working and family lives, which is often overlooked. 32 This highlights relapse reduction as a worthy treatment goal in MS.
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Regular MRI follow-up data were not available for the group of patients in this study. MRI after the first year of treatment with IFN-β can be a good predictor of the outcome at 4 years, 35 and the occurrence of two or more new T2 lesions or new gadolinium-enhancing lesions in patients with variable responses to IFN-β associates a significantly increased risk of future relapses and progression.
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In this study, we intended to determine whether pretreatment activation of pSTAT4 predicts longer term outcome. Therefore, we did not assess the medium-or long-term effects of IFN-β treatment on STAT4 signalling and IFNAR expression. Subnormal responses to type I IFN in MS can be corrected by long-term IFN-β therapy which is able to prime the subnormal IFN response and elevate STAT signalling levels. 37 Gene expression profiling studies show that the IFN-β deficiency exhibited by patients with MS can be corrected over time by repeated IFN-β administration
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; however, IFN signalling and gene activation pathways are partially resistant to IFN therapy in MS. 2 Of note, the decreased IFN-β response in patients with MS can be improved by combination therapy with other treatments with synergistic effects.
We have previously shown that prior exposure of PBMC of healthy controls and patients with MS to dexamethasone results in increased sensitivity of the cells to IFN-β, to an increase in pSTAT4 generation and in upregulation of its receptor expression. 39 We showed similar enhancement of IFN-β signalling in cells from healthy controls and patients with MS by curcumin. 40 In conclusion, here we show for the first time that IFN-β-induced STAT4 signalling is reduced in untreated patients with MS as compared to healthy subjects. The reduced pSTAT4 induction by IFN-β in patients with MS compared with controls indicates a decreased ability to activate IFN-β signalling pathway via STAT4. This, combined with the reduction in IFNAR expression, suggests that untreated patients with MS have decreased IFN-β responsiveness. Therapeutic strategies to improve this responsiveness, for example, by synergistic combinations may be beneficial in the treatment for MS in the future.
